Programmed death-1 (PD-1) and interactions with PD-ligand 1 (PD-L1) play critical roles in the tumour evasion of immune responses through different mechanisms, including inhibition of effector T cell proliferation, reducing cytotoxic activity, induction of apoptosis in tumour-infiltrating T cells and regulatory T cell (T reg ) expansion. Effective blockade of immune checkpoints can therefore potentially eliminate these detrimental effects. The aim of this study was to investigate the effect of anti-PD-1 antibody, pembrolizumab, on various T reg subpopulations. Peripheral blood mononuclear cells (PBMC) from healthy donors (HD) and primary breast cancer patients (PBC) were treated in vitro with pembrolizumab, which effectively reduced PD-1 expression in both cohorts. We found that PD-1 was expressed mainly on CD4 
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Introduction
Immune checkpoint proteins such as cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) play important roles in peripheral tolerance by regulating negatively the activation of T cell-mediated immune responses. CTLA-4, a homologue of CD28, is expressed on activated T cells, where it outcompetes CD28 in binding to CD80 and CD86, dampens the stimulatory signals and attenuates T cell activation [1, 2] . Similarly, PD-1 is expressed on activated T cells, and upon binding to its ligands (PD-L1 and PD-L2) inhibits T cell functions [3] . In non-pathological conditions, T cells are activated on antigenic stimulation, resulting in the generation of antigen-specific T effector cells, which then target cells expressing that specific antigen. As a control mechanism, activation of T cells also results in the up-regulation of PD-1 on their surfaces, which then binds to PD-L1 and PD-L2, relays inhibitory signals to activated T cells and downmodulates their activation, and thus helps in controlling autoimmunity [1] . However, in chronic infections and pathological conditions such as cancer, due to prolonged and consistent antigenic stimulation, PD-1 expression on T cells remains elevated, leading to 'T cell exhaustion', identified by decreased cytokine production, proliferation and cytotoxic activity [4, 5] . This 'hyporesponsive' state results in their inability to mount immunological responses against the identified antigens [6] . The PD-1/PD-L pathway is thus exploited by various cancers to evade tumourspecific host immune responses, and blockade of these interactions using PD-1 and/or PD-L1-specific antibodies results in partial restoration of T effector cell functions. PD-1 blockade using monoclonal antibodies also results in down-regulation of forkhead box protein 3 (FoxP3) expression in regulatory T cells (T reg ) and prevented T reg -mediated suppression of melanoma antigen-specific cytotoxic T lymphocytes [7] .
Recently, immune checkpoint blockade has emerged as an important approach in developing effective cancer immunotherapies, and the success of recent clinical trials using antibodies targeting CTLA-4 (ipilimumab) [8] , PD-1 (pembrolizumab) [9] , lambrolizumab [10] , nivolumab [11, 12] and PD-L1 (atezolizumab) [13] in various cancers has elicited strong interest supporting this strategy [14] [15] [16] . Ipilimumab, the first approved immune checkpoint inhibitor targeting CTLA-4, improved overall survival in a Phase III clinical trial in metastatic melanoma patients [8, 17] . Pembrolizumab (Keytruda) is a humanized monoclonal immunoglobulin (Ig)G4k antibody [18] , with a strong binding affinity to PD-1 [19] . It evokes a strong antitumour immune response by binding to PD-1 and blocking its interactions with its ligands. Pembrolizumab has been approved for the treatment of metastatic melanoma and has also shown positive responses in patients with triple-negative breast cancer, non-small-cell lung cancer, gastric cancer, advanced bladder cancer and head and neck cancer [16] . However, the effects of pembrolizumab on various T cell subsets and their markers have not yet been investigated fully.
In this study, we investigated the effect of pembrolizumab on different T reg subsets in peripheral blood of healthy donors (HD) and primary breast cancer (PBC) patients. Pembrolizumab effectively blocked PD-1 expression but did not affect the expression of other T reg -related markers. Additionally, we show that pembrolizumab-mediated blockade only affects CD4
1 CD25 2 non-T regs . Our results suggest that pembrolizumab may reverse immune escape through blockage of PD-1/PD-L1 interaction, and not by altering T reg phenotype or function.
Materials and methods

Isolation of peripheral blood mononuclear cells
The study was performed after ethical approval from Al Ain Medical District Research Ethics committee, Al Ain, United Arab Emirates (Protocol no. 13/23-CRD 244/13). All patients and HD provided written informed consent prior to sample collection and all experiments were performed in accordance with relevant guidelines and regulations. Peripheral blood was collected in heparinized tubes from eight HD and eight PBC patients.
Peripheral blood mononuclear cells (PBMC) were isolated from fresh whole blood by density-gradient centrifugation using Histopaque-1077 (Sigma-Aldrich, St Louis, MO, SA).
PBMC were frozen in cryovials at a density of 5 million cells per 1 ml freezing media [50% fetal calf serum (FCS), 40% RPMI-1640 media and 10% dimethylsulphoxide (DMSO)] to be used in batches for subsequent staining and analysis.
PBMC treatment with pembrolizumab
Freshly thawed PBMC were suspended at 2 3 10 6 cells/well in 2 ml complete medium (RPMI-1640 supplemented with 2 mM L-glutamine, 10% FCS and 1% penicillin/streptomycin); 24-well non-treated culture plates were precoated with plate-bound 2 lg/ml anti-CD3 antibody [muromonab-CD3 (OKT3) clone; eBioscience, San Diego, CA, USA] and 2 lg/ml anti-CD28 antibody (CD28.2 clone; eBioscience) for 2Á5 h at 378C. PBMC were either plated as 'non-activated' in non-coated wells or 'activated' in precoated wells. Plated cells were then treated with anti-PD-1 monoclonal antibody, Keytruda (pembrolizumab; Merck, Kenilworth, NJ, USA) at different concentrations (0, 1, 2, 5 and 10 mg/ml), and were incubated for 24 h in a humidified incubator at 378C and 5% CO 2 .
Multi-parametric flow cytometry
After treatment, cells were collected in fluorescence activated cell sorter (FACS) tubes, washed and resuspended in 100 ml staining buffer [phosphate-buffered saline (PBS) with 2% FCS and 0Á1% sodium azide]. Cells were then blocked for Fc receptor using FcR Blocker (Miltenyi Biotec, Bergisch Gladbach, Germany), and surface and intracellular staining were performed as described previously [20] . To gate out dead cells, Fixable Viability Dye eFluor V R 660 (FVD 660; eBioscience) was used. The following antibodies were used for staining: CD3-allophycocyanin (APC)-H7 (clone SK-7; BD Biosciences, Oxford, UK), CD4-Alexa Fluor 700 (clone RPA-T4, BioLegend, San Diego, CA, USA), CD25-phycoerythrin cyanin 7 (PE/Cy7; clone M-A251, BioLegend), latency-associated peptide-phycoerythrin (LAP-PE) (clone Tw4-2F8; BioLegend), PD-1-PE/Dazzle TM 594 (clone EH12.2H7; BioLegend), PD-1-peridinin chlorophyll (PerCP)-eFluor V R 710 (clone J105; eBioscience), cytotoxic T lymphocyte antigen 4 (CTLA-4)-PerCP-eFluor V R 710 (clone 14D3; eBioscience), CD15s-APC (clone CSLEX1; BD Biosciences), Ki-67-PerCP/Cy5.5 (clone B56; BD Biosciences), forkhead box protein 3 (FoxP3)-PE-Cy7 (clone PCH101; eBioscience) and Helios-fluorescein isothiocyanate (FITC) (clone 22F6; BioLegend).
All data were acquired with a BD FACSCanto II flow cytometer using BD FACSDiva software (BD Biosciences) and analysed on BD FACSuite software (BD Biosciences).
Statistical analyses
All statistical analyses were performed using GraphPad Prism version 5.0 software (GraphPad Software, Inc., San Diego, CA, USA) and Microsoft Excel (Microsoft Corporation, Washington DC, USA). The Shapiro-Wilk normality test followed by paired/Wilcoxon's matched-pairs signedrank test or unpaired/Mann-Whitney tests were used to examine the differences within groups or between groups, respectively. Data are represented as mean 6 standard error of the mean (s.e.m.). A P-value < 0Á05 was considered statistically significant.
Results
Pembrolizumab effectively blocks PD-1 but does not affect CTLA-4 expression in non-activated and activated T cells states (HD, 8Á9 6 0Á8 versus 7Á4 6 1Á3 and PBC, 14Á8 6 1Á5 versus 14Á3 6 1Á7; Fig. 1c,f) .
PD-1 is expressed mainly on CD4 (Fig. 2a,b) . There was nearly 90% reduction in PD-1 expression in CD4 1 CD25 2 T cells after pembrolizumab treatment compared to approximately 20% reduction in PD-1 expression in CD4 1 CD25 1 T cells after treatment in HD and PBC patients (Fig. 2c) . [21] , and Helios expression is essential for their suppressive characteristics [22] [23] [24] . Representative flow cytometric plots for FoxP3 and Helios expression in CD4
Levels of different subsets of FoxP3
1 T cells in non-activated and activated PBMC from HD and PBC are shown in Fig. 3a and HD and PBC in non-activated (Fig. 3b,c ) and activated states (Fig. 3e,f) . and LAP expression in different T reg subsets are shown in Fig. 4a . CD15s expression in HD was observed mainly in the FoxP3 2 Helios 1 T reg subset (36Á8 6 7Á3%), which was significantly higher compared with its expression in FoxP3 1 Helios 1 (11Á2 6 1Á2%) and FoxP3 1 Helios 2 (7Á7 6 1Á4%) T reg subsets in the non-activated state (Fig. 4a) . Interestingly, the CD15s expression pattern was different in PBC patients compared to HD (Fig. 4a,b) . In PBC patients, CD15s expression was observed mainly in the FoxP3 1 Helios 2 T reg subset (20Á7 6 6Á4%), followed by (Fig. 4b) . LAP expression also remained unaffected in different FoxP3/ Helios subsets in non-activated and activated settings in the study cohorts (data not shown).
Discussion
T cell-mediated immune response relies primarily on antigen recognition by the T cell receptor (TCR). Various costimulatory and inhibitory pathways are involved in the regulation of T cell responses under normal pathological conditions. Interactions between PD-1 and its ligand PD-L1 regulate peripheral tolerance via down-regulation of effector T cell levels, induction of apoptosis of tumour- infiltrating T cells and promoting CD4 1 T cell differentiation into suppressive FoxP3 1 T reg [26] , thereby providing an immune permissive environment for tumours to progress. Effective blockade of PD-1/PD-L1 can eradicate these deleterious effects of T cell-mediated immunity in cancer progression [2, 27] .
Pembrolizumab was the first anti-PD-1 antibody approved by the Food and Drug Administration (FDA) given to patients with metastatic melanoma [9] . PD-L1 expression was associated with poor prognosis in a study conducted by Qin et al. [28] , who assessed correlations between PD-L1 expression and patient clinical characteristics in 870 breast cancer patients, and recently a clinical trial has assessed the safety profile and anti-tumour efficacy of pembrolizumab in triple-negative breast cancer patients that have shown acceptable safety and promising antitumour effects [29] , with Phase II trials currently under way (clinicaltrials.gov identifier: NCT02447003). Additionally, Adams et al. [30] reported a remarkable response to combination therapy consisting of pembrolizumab and Nab-paclitaxel in a patient with metaplastic breast cancer, associated commonly with over-expression of PD-L1 [31] , as part of an ongoing clinical trial (clinicaltrials.gov identifier: NCT02752685).
In the present study, we investigated the effect of pembrolizumab on various T reg -associated molecules, and compared between HD and PBC patients. T reg are comprised mainly of thymic-derived T reg and peripheral T reg , which are broadly recognized by CD25 and FoxP3 expression [22] . FoxP3 is a key transcription factor responsible for their functional characteristics, as shown by the development of autoimmune/inflammatory disease, following FoxP3 1 T reg depletion [32] . The prognostic significance of FoxP3 1 T reg in breast cancer is contradictory; however, as the majority of studies in solid malignancies have shown reduced survival with expanded FoxP3 T reg , some studies have reported a favourable association between T reg expansion and survival; for instance, in oestrogen receptornegative breast cancer [33, 34] . We have recently reported an expansion of CD4
1 FoxP3 1 Helios 1 T reg in the tumour microenvironment (TME) of breast cancer patients and have suggested a negative prognosis based on the coexpression of immune inhibitory molecules, including CTLA-4 and PD-1 [20] . Additionally, we reported that tumour-infiltrating CD4 1 and CD8 1 T cells show similar PD-1 expression in PBC patients [20] . In the present study, we found that PD-1 expression on circulating CD4 1 T reg in PBC patients is reduced effectively by pembrolizumab.
PD-1 is expressed on exhausted T cells, which results in inhibition of T cell proliferation, cytokine secretion and cytotoxic effects through various pathways [1] , while CTLA-4 is expressed constitutively on T reg and is upregulated on activated T cells. CTLA-4 affects T cellmediated immunosuppression and peripheral tolerance greatly, as shown by the spontaneous T reg proliferation and development of autoimmune disorders in CTLA-4-deficient mice [35] . Furthermore, genetic polymorphisms in PD-1 and CTLA-4 have been associated with increased risk of developing breast cancer [36] . The unaffected CTLA-4 expression in T cells following pembrolizumab treatment in our study confirmed the distinct pathways employed by PD-1 and CTLA-4 in immune inhibition.
We have reported that PD-1 is expressed mainly on CD4
1
CD25
1 T cells, and pembrolizumab has a greater effect on PD-1 expression in CD4 1 CD25 2 T cells that are comprised of non-T reg and/or non-activated T cells. Peripheral T regs are induced from naive T regs via peripheral antigen presentation [21] . Su et al. [37] suggested blocking of naive CD4 1 T cell recruitment as an effective mechanism to reverse immunosuppression in breast cancer. Additionally, Plitas et al. [38] showed an expansion of suppressive intratumoral T regs in breast cancer with distinct gene expression compared to circulating T regs . In addition to FoxP3, the Ikaros zinc finger transcription factor, Helios and CD15s (Sialyl Lewis x) have been linked to the suppressive potential of T regs . Miyara et al. [25] 
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